P. Easterbrook
World Health Organization
1 Papers
P. Easterbrook is an academic researcher from World Health Organization. The author has contributed to research in topics: Viral load & Lopinavir. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial.
Nicholas I. Paton,Nicholas I. Paton,Cissy Kityo,Jennifer Thompson,Immaculate Nankya,Leonard Bagenda,Anne Hoppe,James Hakim,Andrew Kambugu,Joep J. van Oosterhout,Joep J. van Oosterhout,Mary Kiconco,Silvia Bertagnolio,Philippa Easterbrook,Peter Mugyenyi,A. Sarah Walker,E. Agweng,P Awio,G. Bakeinyaga,C. Isabirye,U. Kabuga,S. Kasuswa,M. Katuramu,C Kityo,F. Kiweewa,H. Kyomugisha,E. Lutalo,P. Mugyenyi,D. Mulima,Hellen Musana,G. Musitwa,Victor Musiime,M. Ndigendawan,H. Namata,J. Nkalubo,P. Ocitti Labejja,P. Okello,P. Olal,G. Pimundu,P. Segonga,F. Ssali,Z. Tamale,D. Tumukunde,W. Namala,R. Byaruhanga,Joshua Kayiwa,J. Tukamushaba,S. Abunyang,D. Eram,O. Denis,R. Lwalanda,L. Mugarura,J. Namusanje,I. Nankya,Emmanuel Ndashimye,E. Nabulime,O. Senfuma,G. Bihabwa,E. Buluma,P. Easterbrook,A. Elbireer,Andrew Kambugu,D. Kamya,M. Katwere,R. Kiggundu,C. Komujuni,Eva Laker,E. Lubwama,Ivan Mambule,J. Matovu,A. Nakajubi,J. Nakku,R. Nalumenya,L. Namuyimbwa,F. Semitala,Bonnie Wandera,Jane N Wanyama,H. Mugerwa,Abbas Lugemwa,E. Ninsiima,T. Ssenkindu,S. Mwebe,L. Atwine,H. William,C. Katemba,M. Acaku,P. Ssebutinde,H. Kitizo,J. Kukundakwe,M. Naluguza,K. Ssegawa,Namayanja,F. Nsibuka,P. Tuhirirwe,M. Fortunate,J. Acen,J. Achidri,A. Amone,M. Chamai,J. Ditai,M. Kemigisa,M. Kiconco,C. Matama,D. Mbanza,F. Nambaziira,M. Owor Odoi,A. Rweyora,G. Tumwebaze,H. Kalanzi,J. Katabaazi,A. Kiyingi,M. Mbidde,M. Mugenyi,Raymond Mwebaze,P. Okong,I. Senoga,Mary Abwola,D. Baliruno,J. Bwomezi,A. Kasede,M. Mudoola,R. Namisi,F. Ssennono,S. Tuhirwe,George Abongomera,G. Amone,J. Abach,I. Aciro,B. Arach,P. Kidega,J. Omongin,E. Ocung,W. Odong,A. Philliam,Hillary Alima,B. Ahimbisibwe,E. Atuhaire,F. Atukunda,G. Bekusike,A. Bulegyeya,D. Kahatano,S. Kamukama,J. Kyoshabire,A. Nassali,A. Mbonye,T. M. Naturinda,Ndukukire,A. Nshabohurira,H. Ntawiha,A. Rogers,M. Tibyasa,S. Kiirya,Dickens Atwongyeire,A. Nankya,C. Draleku,D. Nakiboneka,D. Odoch,L. Lakidi,R. Ruganda,R. Abiriga,M. Mulindwa,F. Balmoi,S. Kafuma,E. Moriku,J. Hakim,A. Reid,E. Chidziva,Godfrey Musoro,C Warambwa,G. Tinago,S. Mutsai,Mackwellings Phiri,S. Mudzingwa,T. Bafana,V. Masore,C. Moyo,R. Nhema,S. Chitongo,Robert S. Heyderman,Lucky Kabanga,Symon Kaunda,Aubrey Kudzala,Linly Lifa,Jane Mallewa,Michael Moore,Chrissie Mtali,George Musowa,Grace Mwimaniwa,Rosemary Sikwese,Joep J. van Oosterhout,Milton Ziwoya,H. Chimbaka,B. Chitete,S. Kamanga,T. Kayinga E. Makwakwa,R. Mbiya,M. Mlenga,T. Mphande,C. Mtika,G. Mushani,O. Ndhlovu,M. Ngonga,I. Nkhana,R. Nyirenda,P. Cheruiyot,C. M. Kwobah,W. Lokitala Ekiru,M. Mokaya,A. Mudogo,A. Nzioka,Abraham Siika,M. Tanui,S. Wachira,Kara Wools-Kaloustian,P. Alipalli,E. Chikatula,J. Kipaila,I. Kunda,S. Lakhi,J. Malama,W. Mufwambi,L. Mulenga,P. Mwaba,E. Mwamba,Aggrey Mweemba,M. Namfukwe,E. Kerukadho,B. Ngwatu,J. Birungi,N. Paton,J. Boles,Andrew Burke,L. Castle,S. Ghuman,L. Kendall,A. Hoppe,S. Tebbs,Margaret J. Thomason,J. Thompson,Stephen L. Walker,J. Whittle,H. Wilkes,N. Young,Moira J. Spyer,C. Kapuya,F. Kyomuhendo,D. Kyakundi,N. Mkandawire,S. Mulambo,S. Senyonjo,B. Angus,Alejandro Arenas-Pinto,A. Palfreeman,F. Post,David A. Ishola,Jose R. Arribas,Robert Colebunders,Marco Floridia,Marina Giuliano,P. Mallon,P. Walsh,M. De Rosa,E. Rinaldi,I. Weller,Charles F. Gilks,A. Kangewende,E. Luyirika,F. Miiro,P. Mwamba,Sylvia Ojoo,Sam Phiri,J.J. van Oosterhout,A. Wapakabulo,Tim E. A. Peto,Neil French,J. Matenga,G. Cloherty,J van Wyk,M. Norton,S. Lehrman,P. Lamba,K. Malik,James F. Rooney,Wendy Snowden,J. Villacian +284 more
TL;DR: The results do not support the introduction of routine resistance testing in ART programmes in low-income settings for the purpose of selecting second-line NRTIs and Genotypic resistance testing might not accurately predict NRTI activity in protease inhibitor-based second- line ART.
78